Researchers at the University of Utah tested many toxins in the omaria cone snail’s venom and found that Om1A is unique because it fits tightly into some receptors but not others. This desirable attribute is beneficial because if a drug can be developed to mimic the shape of the toxin, it will be less likely to bind with the wrong receptor and cause unwanted side effects. This slow but steady work will someday hopefully transform the omaria cone snail’s debilitating bite into medicine that gives mobility back to people with Parkinson’s disease.